Showing 1781-1790 of 5631 results for "".
- ASRS Announces Virtual Annual Scientific Meeting July 24-26, 2020https://modernod.com/news/asrs-announces-virtual-annual-scientific-meeting-july-24-26-2020/2477759/Due to the COVID-19 pandemic, the American Society of Retina Specialists (ASRS) has decided to hold its annual meeting online. In a letter to membership, Timothy Murray, MD, MBA, ASRS President, and Philip Ferrone, MD, Program Chair, said that the ASRS Board of Directors has concluded that
- CMS Issues Final 2021 ASC Payment Rule: 2.4% Increase for Facilitieshttps://modernod.com/news/cms-issues-final-2021-asc-payment-rule-2-4-increase-for-facilities/2478624/On December 2, the Centers for Medicare and Medicaid Services (CMS) issued its final CY 2021 payment rate regulation for hospital outpatient departments (HOPD) and ambulatory surgery centers (ASC). ASC Payme
- Aura Biosciences Names Mark De Rosch, PhD, Chief Operating Officerhttps://modernod.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/Aura Biosciences announced the appointment of Mark De Rosch, PhD, as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy. Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and deve
- Medicare Plans to Phase in Changes for Office-Visit Paymentshttps://modernod.com/news/medicare-plans-to-phase-in-changes-for-office-visit-payments/2479706/The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services, according to a Medscape
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- MatterHackers COVID-19 Response Registry: Medical Facilities and Government Agencies (USA)https://modernod.com/news/matterhackers-covid-19-response-registry-medical-facilities-and-government-agencies-usa/2477523/Matterhackers, a provider of 3D printing solutions, is looking for medical professionals or government agencies in need of emergency equipment for COVID-19 treatment. The company has engaged thousands in their 3D printing community–both at-home 3D printing providers as well as larger corpo
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- HHS Allocates Another $4B in COVID-19 Relief Funds to Rural Facilities, Safety Net Hospitalshttps://modernod.com/news/hhs-allocates-another-4b-in-covid-19-relief-funds-to-rural-facilities-safety-net-hospitals/2478004/The Department of Health and Human Services (HHS) is allocating approximately $3 billion to safety net hospitals and another $1 billion in COVID-19 relief funds to certain rural providers and others in small metropolitan areas, according to a FierceHealthcare
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using